🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

Recruitingn/aAges any - anyAllHumanity and Health Research Centre
NCT02863757 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Liver biopsy proved CHB and/or NAFLD at baseline; * Chinese * Follow-up duration\>12 months Exclusion Criteria: * Other liver diseases; * Secondary causes of hepatic steatosis; * Alcohol abuse; * Liver cirrhosis, cirrhosis related complications or HCC at baseline; * Malignancy; * History of liver transplantation
💊

What it tests

  • Not listed
📍

Where

1 site
Humanity and Health GI and Liver Centre
Hong Kong, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy